Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma with EGFR Mutation

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800016339

Enrollment

Unknown

Registered

2018-05-25

Start date

2018-08-01

Completion date

Unknown

Last updated

2018-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Adenocarcinoma

Interventions

Case series:berberberine in combination with egfr-tki

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. aged=18 years; 2. ECOG 0-2; 3. normal hematology function, coagulation function, liver function and kidney function; 4. Non - squamous non small cell lung cancer((NSCLC)) has been pathologically diagnosed; 5. TNM stage IV patients according to JACC version 8; 6. Measurable or evaluable tumor patients (according to RECIST1.1 criteria); 7. EGFR exon 19 deletion (19del) or exon 21 mutation (L858R) has been confirmed.

Exclusion criteria

Exclusion criteria: 1. Patients who have had or have had any malignant tumors in the past 5 years except those who have been treated for basal or squamous cell carcinoma of the skin, cervical or bladder, and breast carcinoma in situ; 2. Patients who are allergic to berberberine; 3. Patients who have received chemotherapy for tumor metastasis; 4. Patients who have received drugs targeting EGFR or VEGF to treat lung cancer; 5. During pregnancy.

Design outcomes

Primary

Measure	Time frame
CT;blood examination;	—

Countries

China

Contacts

Public ContactCheng Huang

Fujian Provincial Cancer Hospital (FPCH)

yaoshi0394@sina.com+86 13905010379

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026